Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Agilentís PD-L1 assay offers new indication
July 2017
SHARING OPTIONS:

SANTA CLARA, Calif.—Agilent Technologies Inc. is now offering expanded access to a test for PD-L1 in Europe to aid physicians in making better-informed treatment decisions for patients with urothelial cancer (UC). This makes Europe the first region to launch a PD-L1 CE-IVD test for this cancer type globally. The test in question, PD-L1 IHC 28-8 pharmDx, is CE marked for the detection of tumor cell PD-L1 expression for non-squamous, non-small-cell lung cancer, melanoma and squamous cell carcinoma of the head and neck. It now boasts more clinically validated tissue indications than any other commercially manufactured PD-L1 assay on the market, according to an Agilent press release. For this latest indication in UC, a recent clinical study demonstrated that tumor PD-L1 expression, as determined by PD-L1 IHC 28-8 pharmDx, could help identify UC patients that are likely to respond to treatment with Opdivo.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.